Cargando…

Peripheral Blood Lymphocyte Subsets Predict the Efficacy of Immune Checkpoint Inhibitors in Non–Small Cell Lung Cancer

BACKGROUND: Non–small cell lung cancer (NSCLC) has entered the era of immunotherapy. However, only partial patients were able to benefit from immune checkpoint inhibitors (ICIs). Currently, biomarkers for predicting patients’ response to ICIs are primarily tumor tissue dependent and have limited acc...

Descripción completa

Detalles Bibliográficos
Autores principales:	Miao, Kang, Zhang, Xiaotong, Wang, Hanping, Si, Xiaoyan, Ni, Jun, Zhong, Wei, Zhao, Jing, Xu, Yan, Chen, Minjiang, Pan, Ruili, Wang, Mengzhao, Zhang, Li
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Frontiers Media S.A. 2022
Materias:	Immunology
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9283649/ https://www.ncbi.nlm.nih.gov/pubmed/35844502 http://dx.doi.org/10.3389/fimmu.2022.912180

Ejemplares similares

Corrigendum: Peripheral blood lymphocyte subsets predict the efficacy of immune checkpoint inhibitors in non– small cell lung cancer
por: Miao, Kang, et al.
Publicado: (2022)

Real-World Data of Different Immune Checkpoint Inhibitors for Non-Small Cell Lung Cancer in China
por: Miao, Kang, et al.
Publicado: (2022)

Analysis of cytokines in bronchoalveolar lavage fluid in patients with checkpoint inhibitor pneumonitis and pulmonary infection: A case–control study
por: Si, Xiaoyan, et al.
Publicado: (2023)

The development of a tumor‐associated autoantibodies panel to predict clinical outcomes for immune checkpoint inhibitor‐based treatment in patients with advanced non‐small‐cell lung cancer
por: Zhao, Jing, et al.
Publicado: (2023)

Leptomeningeal enhancement in magnetic resonance imaging predicts poor prognosis in lung adenocarcinoma patients with leptomeningeal metastasis
por: Gao, Xiaoxing, et al.
Publicado: (2022)

Abivertinib in patients with T790M‐positive advanced NSCLC and its subsequent treatment with osimertinib
por: Wang, Hanping, et al.
Publicado: (2020)

Clinical characteristics and prognostic model for extensive‐stage small cell lung cancer: A retrospective study over an 8‐year period
por: Ni, Jun, et al.
Publicado: (2021)

Camrelizumab plus platinum-irinotecan followed by maintenance camrelizumab plus apatinib in untreated extensive-stage small-cell lung cancer: a nonrandomized clinical trial
por: Ni, Jun, et al.
Publicado: (2023)

Re-biopsy status among Chinese non-small-cell lung cancer patients who progressed after icotinib therapy
por: Wang, Hanping, et al.
Publicado: (2018)

Prediction of major adverse cardiac events is the first critical task in the management of immune checkpoint inhibitor‐associated myocarditis
por: Xu, Yan, et al.
Publicado: (2022)

Clinical characteristics and outcomes of immune checkpoint inhibitor-induced diabetes mellitus
por: Liu, Jia, et al.
Publicado: (2022)

Genomic characteristics of driver genes in Chinese patients with non‐small cell lung cancer
por: Si, Xiaoyan, et al.
Publicado: (2020)

Treatment with or without bevacizumab as a first‐line and maintenance therapy for advanced non‐squamous non‐small cell lung cancer: A retrospective study
por: Jun, Ni, et al.
Publicado: (2020)

Management of immune checkpoint inhibitor‐related dermatologic adverse events
por: Si, Xiaoyan, et al.
Publicado: (2019)

Clinical diagnosis and treatment of immune checkpoint inhibitor‐associated pneumonitis
por: Wang, Hanping, et al.
Publicado: (2019)

Recommendations and exploration of diagnosis and treatment of critical and refractory immune checkpoint inhibitor‐associated adverse events
por: Song, Peng, et al.
Publicado: (2020)

Case Report: THSD7A-Positive Membranous Nephropathy Caused by Tislelizumab in a Lung Cancer Patient
por: Chen, Minjiang, et al.
Publicado: (2021)

Study protocol of KeyPemls‐004: A phase 2 study of pembrolizumab in combination with plinabulin and docetaxel in previously treated patients with metastatic non‐small cell lung cancer and progressive disease (PD) after immunotherapy (PD‐1/PD‐L1 inhibitor) alone or in combination with platinum‐doublet chemotherapy
por: Liu, Jia, et al.
Publicado: (2023)

Clinical recommendations on diagnosis and treatment of immune checkpoint inhibitor‐induced renal immune‐related adverse events
por: Zheng, Ke, et al.
Publicado: (2020)

Management of immune checkpoint inhibitor‐related adverse events: A review of case reports
por: Si, Xiaoyan, et al.
Publicado: (2020)

Successful treatment of pulmonary inflammatory myofibroblastic tumor with platinum‐pemetrexed: The first report of two cases
por: Si, Xiaoyan, et al.
Publicado: (2020)

Histologic transformation of lung cancer during pembrolizumab therapy: A case report
por: Si, Xiaoyan, et al.
Publicado: (2020)

The alterations in peripheral lymphocyte subsets predict the efficacy and prognosis of immune checkpoint inhibitors in hepatocellular carcinoma
por: Xie, Qu, et al.
Publicado: (2023)

Imbalance of Peripheral Lymphocyte Subsets in Patients With Ankylosing Spondylitis: A Meta-Analysis
por: Liu, Dong, et al.
Publicado: (2021)

Clinical diagnosis and treatment recommendations for ocular toxicities of targeted therapy and immune checkpoint inhibitor therapy
por: Liu, Xiaowei, et al.
Publicado: (2020)

Changes in T Lymphocyte Subsets in Different Tumors Before and After Radiotherapy: A Meta-analysis
por: Wang, Qin, et al.
Publicado: (2021)

Characterization of Somatic Mutations That Affect Neoantigens in Non-Small Cell Lung Cancer
por: Liang, Hongge, et al.
Publicado: (2022)

The predictive value of peripheral blood cells and lymphocyte subsets in oesophageal squamous cell cancer patients with neoadjuvant chemoradiotherapy
por: Zhou, Jin, et al.
Publicado: (2022)

Nimotuzumab combined with chemotherapy as first‐line treatment for advanced lung squamous cell carcinoma
por: Si, Xiaoyan, et al.
Publicado: (2018)

Association Between Response to Nivolumab Treatment and Peripheral Blood Lymphocyte Subsets in Patients With Non-small Cell Lung Cancer
por: Ottonello, Selene, et al.
Publicado: (2020)

Safety and efficacy of immune checkpoint inhibitors in non-small cell lung cancer patients with preexisting antinuclear antibodies: a retrospective cohort study
por: Zhang, Dongming, et al.
Publicado: (2022)

A nomogram model based on peripheral blood lymphocyte subsets to assess the prognosis of non-small cell lung cancer patients treated with immune checkpoint inhibitors
por: Xu, Xiaoling, et al.
Publicado: (2021)

Comparison of T and NK lymphocyte subsets between human endometrial tissue and peripheral blood
por: Chernyshov, Viktor P., et al.
Publicado: (2019)

Blood Lymphocyte Subsets for Early Identification of Non-Remission to TNF Inhibitors in Rheumatoid Arthritis
por: Rodríguez-Martín, Eulalia, et al.
Publicado: (2020)

Savolitinib versus crizotinib for treating MET positive non‐small cell lung cancer
por: Miao, Kang, et al.
Publicado: (2023)

Clinical characteristics and management of immune checkpoint inhibitor‐related pneumonitis: A single‐institution retrospective study
por: Wang, Hanping, et al.
Publicado: (2020)

Diversity of Dominant Peripheral T Cell Receptor Clone and Soluble Immune Checkpoint Proteins Associated With Clinical Outcomes Following Immune Checkpoint Inhibitor Treatment in Advanced Cancers
por: Li, Ye, et al.
Publicado: (2021)

B-Lymphocyte Phenotype Determines T-Lymphocyte Subset Differentiation in Autoimmune Diabetes
por: Egia-Mendikute, Leire, et al.
Publicado: (2019)

Prognostic Factors and Survival Benefits of Antitumor Treatments for Advanced Non-Small Cell Lung Cancer Patients With Central Nervous System Metastasis With or Without Driver Genes: A Chinese Single-Center Cohort Study
por: Gao, Xiaoxing, et al.
Publicado: (2022)

Clinical manifestation and management of immune checkpoint inhibitor‐associated cardiotoxicity
por: Guo, Xiaoxiao, et al.
Publicado: (2019)

Cannot write session to /tmp/vufind_sessions/sess_4pegk2ej668nkfoej9h5kjqtth